Evofem Biosciences, Inc.

Thank you for standing by, and welcome to the FFM Biosciences Third Quarter 2021 Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star 1 on your telephone. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Amy Raskoff, Vice President of Investor Relations. Please go ahead.

Thank you. Good afternoon, everyone, and welcome to the EvoFem Biosciences results call for the third quarter of 2021. If you haven't done so already, I encourage you to access the press release we issued earlier today and the presentation that accompanies this call, both of which are at evofem.com under the Investors tab. Before we begin, I would like to remind you that remarks on this call will contain forward-looking statements, which are made only as of today, November 15, 2021. For a more detailed description of important risk factors that could cause our actual results to differ materially, please refer to our annual report on Form 10-K and our most recently filed 10-Q. With that, I'll turn the call over to EvoFem's CEO, Sandra Pelletier.

Thank you, Amy, and thank you, everyone, for joining us today. Our focus on driving awareness and uptake for FEXI for hormone-free birth control enabled us to reach new heights for the fourth consecutive quarter. The substantial sexy growth in Q3 and Q4 to date is being elevated by the House Rules DTC campaign starring Emmy Award-winning actress Annie Murphy, which we launched on September 9th, as well as the ongoing work of our sales force with OBGYNs, nurse practitioners, and midwives. More than 19,000 prescriptions were filled in Q3, which is a 48% increase from Q2. Q4 is off to a strong start with a spectacular October. Monthly total prescriptions, which jumped to over 7,800 in September, grew 27% to a new record high in October. I'll discuss other metrics and ongoing initiatives in greater detail after our CFO, Jay Files, reviews the financial results. Jay? Thank you, Sandra.